SummaryThe antihypertensive effect of bendrofluazide 5 mg, long‐acting propranolol 160 mg, and the combination of these doses of bendrofluazide and long‐acting propranolol (Inderex)** was assessed in a double‐blind, cross‐over study in 25 patients with essential hypertension. Each treatment was given for four weeks and measurements were made 24 hours after the last dose. All three treatments produced a significant reduction of systolic and diastolic blood pressure. However, the combination product produced a greater reduction in systolic blood pressure than with the single treatments and helped counteract diuretic‐induced hypokalaemia. The combination of bendrofluazide and long‐acting propranolol in a single capsule (Inderex) proved an effective and well tolerated treatment for hypertension that may help improve patients' compliance with treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.